Brevan Howard Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Brevan Howard Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81.2K	Sell	39,018 -23,388	-37%	-$51.4K	﹤0.01%	1998
2026 Q1	$152K	Sell	62,406 -8,023	-11%	-$16.1K	﹤0.01%	1964
2025 Q4	$96.5K	Buy	+70,429	New	+$92.9K	﹤0.01%	1676
2025 Q3	–	Sell	-81,843	Closed	-$92.5K	–	1917
2025 Q2	$92.5K	Sell	81,843 -163,774	-67%	-$218K	﹤0.01%	1788
2025 Q1	$359K	Buy	245,617 +158,044	+180%	+$298K	﹤0.01%	810
2024 Q4	$187K	Buy	87,573 +24,515	+39%	+$60.5K	﹤0.01%	920
2024 Q3	$177K	Buy	63,058 +3,353	+6%	+$8.94K	﹤0.01%	1014
2024 Q2	$139K	Buy	59,705 +27,519	+85%	+$81.2K	﹤0.01%	941
2024 Q1	$144K	Sell	32,186 -65,934	-67%	-$275K	﹤0.01%	853
2023 Q4	$315K	Buy	98,120 +79,743	+434%	+$226K	﹤0.01%	696
2023 Q3	$58.3K	Buy	+18,377	New	+$80.5K	﹤0.01%	360

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Brevan Howard Capital Management's ALLO Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Allogene Therapeutics (ALLO) stake by 37% in Q2 2026, selling an estimated $51.4K and leaving 39,018 shares worth $81.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1998.

Brevan Howard Capital Management first reported a position in ALLO in Q3 2023 and has held it in 11 quarters since. The position peaked at $359K in Q1 2025. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Brevan Howard Capital Management held 39,018 shares of Allogene Therapeutics worth $81.2K as of Q2 2026.
Brevan Howard Capital Management sold 23,388 Allogene Therapeutics shares in Q2 2026, an estimated $51.4K.
Allogene Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1998 holding.
Brevan Howard Capital Management first reported a position in Allogene Therapeutics in Q3 2023 and has held it in 11 quarters since.
Brevan Howard Capital Management's Allogene Therapeutics position peaked at $359K in Q1 2025.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.